drugset / Trial / NCT00227500
Pravastatin for Hyperlipidaemia in HIV.
Phase 4
Completed
40 enrolled
Kirby Institute
Garvan Institute of Medical Research · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabSt Vincent's Hospital, Sydney · collabThe University of New South Wales · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.
Timeline
- Start
- 2001-07
- Primary completion
- —
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pravastatin | Small molecule | 40 mg | — |